Ih-Jen Su, MD, PhD
Ih-Jen Su, MD., PhD. is currently the Chair Professor of the Department of Pathology, National Cheng Kung Univ. Medical College, and the Deputy Superintendent of the NCKU Hospital. He is the jointly appointed Distinguished Investigator of the Division of Infectious Diseases, National Health Research Institutes, Taiwan. Dr. Su obtained his MD and PhD degrees from National Taiwan University College of Medicine and become the full professor ( 1991- ) and Chairman ( 2000-2002 ) of the Department and Institute of Pathology, NTU. Dr. Su is a world-renowned expert pathologist in lymphoma/leukemia research and is the member of International Lymphoma Study Group ( ILSG ). His major research interests are on the pathogenesis and therapy of virus-associated human cancers. He is the pioneering investigator in EBV-associated hemophagocytic syndrome and T cell lymphoma.
In the past 10 years, he devoted himself to the control of infections diseases such as influenza, enteroviruses, and tuberculosis in Taiwan. In 2003-2004, he served as the Director General of Taiwan Center for Disease Control ( CDC ) and successfully controlled the SARS outbreak. He is the President consultant for swine H1N1 control 2009-2010. In recent years, he identified the pre-S mutants in ground glass hepatocytes as the viral oncoproteins in HBV hepatocarcinogenesis and open an entirely new mechanism in HBV hepatocarcinogenesis.
Many of his discoveries from his basic research are at the stage of clinical application and targeted therapy, such as the application of PPAR agonists and resveratrol in the chemoprevention and therapy of virus-associated hemophagocytic syndrome and cancers. He served as a board member for many foundations, and is currently the associate editor of Cancer Science. He has received many prestigious awards for his contributions in research, SARS control, and community service over the past 30 years.